rss
Br J Ophthalmol 2004;88:17-18 doi:10.1136/bjo.88.1.17
  • Clinical science
    • Scientific reports

Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia

  1. C Chen1,
  2. D Louis1,
  3. T Dodd2,
  4. J Muecke1
  1. 1Ophthalmic Oncology Unit, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
  2. 2Institute of Medicine and Veterinary Science, Frome Road, Adelaide, SA 5000, Australia
  1. Correspondence to: Dr James Muecke Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia; raheyesmail.rah.sa.gov.au
  • Accepted 5 April 2003

Abstract

Aim: To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).

Method: Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period.

Result: 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12–50, median 25 months) revealed zero recurrences.

Conclusion: MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.

Footnotes

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.